Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.
Oramed Pharmaceuticals Stock Performance
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.21. Analysts predict that Oramed Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oramed Pharmaceuticals
Several large investors have recently made changes to their positions in the stock. Murchinson Ltd. boosted its stake in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after purchasing an additional 320,495 shares during the period. Renaissance Technologies LLC grew its position in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 10,774 shares during the last quarter. Virtu Financial LLC bought a new stake in Oramed Pharmaceuticals during the 1st quarter worth about $68,000. Finally, XTX Topco Ltd acquired a new position in shares of Oramed Pharmaceuticals during the 2nd quarter worth about $40,000. Institutional investors own 12.73% of the company’s stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
See Also
- Five stocks we like better than Oramed Pharmaceuticals
- Following Congress Stock Trades
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Best Aerospace Stocks Investing
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- What is the Dow Jones Industrial Average (DJIA)?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.